| scholarly article | Q13442814 |
| P50 | author | Kristel Van Laethem | Q28743837 |
| Dominique Schols | Q47698773 | ||
| Jan Balzarini | Q31332118 | ||
| P2093 | author name string | Haruo Tanaka | |
| Atsushi Takahashi | |||
| Katrien O François | |||
| Dana Huskens | |||
| Geoffrey Férir | |||
| Bart Hoorelbeke | |||
| P2860 | cites work | Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists | Q24802476 |
| Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping | Q27618183 | ||
| Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120 | Q27635270 | ||
| Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides | Q27639344 | ||
| Structural improvement of unliganded simian immunodeficiency virus gp120 core by normal-mode-based X-ray crystallographic refinement | Q27654249 | ||
| Mechanism by which the lectin actinohivin blocks HIV infection of target cells | Q27657228 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Solution structure of cyanovirin-N, a potent HIV-inactivating protein | Q27764577 | ||
| DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells | Q28138968 | ||
| Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells | Q28288205 | ||
| Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses | Q28616569 | ||
| A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines--establishment and validation. | Q38943963 | ||
| Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities | Q38943968 | ||
| Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. | Q39581340 | ||
| Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. | Q39756219 | ||
| Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. | Q40204965 | ||
| Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes | Q40216885 | ||
| Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. | Q41986204 | ||
| Molecular cloning of actinohivin, a novel anti-HIV protein from an actinomycete, and its expression in Escherichia coli | Q42644711 | ||
| Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein. | Q44104909 | ||
| A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene | Q45176343 | ||
| Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models | Q45670260 | ||
| HIV/SIV glycoproteins: structure-function relationships | Q48042571 | ||
| Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent | Q56763406 | ||
| Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques | Q73814670 | ||
| AIDS models: microbicides could learn from vaccines | Q78029025 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. | Q30909988 | ||
| Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 | Q33374701 | ||
| Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains | Q33627537 | ||
| Whither or wither microbicides? | Q33715907 | ||
| Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. | Q33842989 | ||
| Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors | Q33957283 | ||
| Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy | Q34005185 | ||
| Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection | Q34065091 | ||
| The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. | Q34341843 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes | Q35024164 | ||
| Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development | Q35137168 | ||
| Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus | Q35634404 | ||
| Inhibiting sexual transmission of HIV-1 infection | Q35709090 | ||
| High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization | Q36237904 | ||
| Exploiting the defensive sugars of HIV-1 for drug and vaccine design | Q36802333 | ||
| Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins | Q37511474 | ||
| Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection | Q37568901 | ||
| Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete | Q38327540 | ||
| Carbohydrate binding properties of the stinging nettle (Urtica dioica) rhizome lectin | Q38350612 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3287-3301 | |
| P577 | publication date | 2010-05-24 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope | |
| P478 | volume | 54 |
| Q34123202 | A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets |
| Q24610025 | Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models |
| Q38891044 | Antiviral lectins: Selective inhibitors of viral entry |
| Q34181482 | Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family |
| Q33955239 | Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells |
| Q47227487 | Chemical and Biophysical Approaches for Complete Characterization of Lectin-Carbohydrate Interactions. |
| Q36358780 | Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains |
| Q34162421 | Complement and viral pathogenesis |
| Q29393523 | Current progress and challenges in HIV gene therapy |
| Q39593941 | Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity |
| Q39283283 | Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120. |
| Q37853935 | HIV sexual transmission and microbicides |
| Q38291704 | HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview. |
| Q28086826 | HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth |
| Q37120236 | Lectin-Glycan Interaction Network-Based Identification of Host Receptors of Microbial Pathogenic Adhesins |
| Q55120164 | Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections. |
| Q37712847 | Lectins, Interconnecting Proteins with Biotechnological/Pharmacological and Therapeutic Applications. |
| Q40168596 | NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles |
| Q90649263 | Overview of the role of kinetoplastid surface carbohydrates in infection and host cell invasion: prospects for therapeutic intervention |
| Q45124702 | Peculiarity in crystal packing of anti-HIV lectin actinohivin in complex with α(1-2)mannobiose |
| Q38023086 | Plant made anti-HIV microbicides--a field of opportunity |
| Q34760408 | Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1. |
| Q27675139 | Structural insights into the specific anti-HIV property of actinohivin: structure of its complex with the α(1–2)mannobiose moiety of gp120 |
| Q37824811 | Targeting cell entry of enveloped viruses as an antiviral strategy. |
| Q38239575 | Targeting strategies for delivery of anti-HIV drugs |
| Q28552932 | The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition |
| Q27696185 | The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120 |
| Q37036454 | The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism |
| Q45147083 | The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity |
| Q35604541 | The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry |
| Q28533345 | The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications |
| Q37424913 | The lectin-like protein 1 in Lactobacillus rhamnosus GR-1 mediates tissue-specific adherence to vaginal epithelium and inhibits urogenital pathogens. |
| Q39224771 | The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents |
| Q36327928 | The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin |
Search more.